Class Information

Class Information

3 Day 7/17-7/19/24 Virtual STI Intensive
Starting:
7/17/2024
Ending:
7/19/2024
Status:
Closed
Location:
Virtual Classroom, MD
Cost:
FREE
Credit Hours:
15.25



This three-day course is open to clinicians offering STI services.  This class is for clinicians that examine patients.  Class size is limited to 45 participants. Continuing Education is provided. Schedule – class schedule set annually.  This 3 Day STI Intensive will be held virtually July 17-19, 2024.

 

OBJECTIVES

1.     Identify the sites from which specimens should be obtained.

2.     Discuss STI Diagnosis.

3.     Describe the management of STIs.

4.     Describe the role of the disease intervention specialist (DIS) in STI control.

5.     Describe the importance of interprofessional collaboration in health department and

        private practice regarding STIs.

Origination Date: 10/28/2020

Renewal Date:10/28/2022

Expiration Date:  10/28/2024

ACCREDITATION STATEMENTS:

 

 

 CDC accreditation logo 0820

 

In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and STD/HIV Prevention Training Center at Johns Hopkins, Mid Atlantic AIDS Education and Training Center and Virginia Department of Health. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME:  The Centers for Disease Control and Prevention designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE:  The Centers for Disease Control and Prevention designates this activity for 15.2 nursing contact hours.

CEU:  The Centers for Disease Control and Prevention is authorized by IACET to offer 1.5 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 15.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 15.5. CDC provider number 98614.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 16.0 CPH recertification credits for this program.

 

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.   

 

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Mr. Gilman and he wishes to disclose that he compensated participants in a Diabetes and Heart Failure App Usability Study.  Also Dr. Tuddenham wishes to disclose that she gets royalties from UpToDate.  She gets an honorarium for editing issues on STIs from Elsevier.  She has no financial-participant in research supported by in-kind donations to Johns Hopkins University by Hologic.  

All of the relevant financial relationships listed for these individuals have been mitigated.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Mr. Ted Heck’s discussion of LGBTW Health Basics.  They will be discussing the use of hormones for gender transition, technically off-label per the FDA still, although endorsed by the Endocrine Society, the AMA, and other major medical institutions, will be mentioned.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.



Jeanne Hoover 4102061156 jhoover6@jhmi.edu